2022
End-of-Life Care for Patients With Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer Therapy
Dzimitrowicz H, Wilson L, Jackson B, Spees L, Baggett C, Greiner M, Kaye D, Zhang T, George D, Scales C, Pritchard J, Leapman M, Gross C, Dinan M, Wheeler S. End-of-Life Care for Patients With Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer Therapy. JCO Oncology Practice 2022, 19: e213-e227. PMID: 36413741, PMCID: PMC9970274, DOI: 10.1200/op.22.00401.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaOral anticancer agentsDays of lifeRenal cell carcinomaEOL careSystemic therapySEER-MedicareHospital deathCell carcinomaLife careIntensive care unit admissionCancer informationAggressive EOL careHigh-quality EOLOral anticancer therapySystemic therapy useCare unit admissionMultivariable logistic regressionQuality of endUnit admissionED visitsOlder patientsYounger patientsHospital admissionTherapy use
2017
Primary care physician continuity and end-of-life care intensity among Medicare cancer decedents.
Wang S, Cramer L, Pollack C, Gross C. Primary care physician continuity and end-of-life care intensity among Medicare cancer decedents. Journal Of Clinical Oncology 2017, 35: 38-38. DOI: 10.1200/jco.2017.35.5_suppl.38.Peer-Reviewed Original ResearchDay of deathLife care intensityCancer diagnosisCancer decedentsCare continuityCare indexCare intensityLife careEnd Results-Medicare databaseIntensive care unit admissionPrimary care physician continuityPrimary care physician's careIntensity of endLife care patternsCare unit admissionOutpatient clinic visitsEmergency department visitsMonths of diagnosisLife care qualityPCP visitsPhysician continuityUnit admissionHospital deathICU admissionClinic visits